Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (502)	4/26/2001 9:48:04 PM
From: Spekulatius	Respond to of 804

T- sales are stagnant - 17M$ for Q1/2001 versus 16.8M$ for Q4/2000. This has taken away the growth appeal from CELG and put pressure on the stock. That said, I have been a buyer for CELG and established a sizeable position for the first time. I think CELG should be able to reignate T growth with new indications and clinical progress with other programs looks good. With plenty of cash at hand and currently operating at breakeven, this appears to be an opportunity to buy in a top notch biotech at distressed prices.